ABSTRACT
Vishu Chandrasekhar, BA
Research Student
Massachusetts General Hospital
Flushing, New York, United States
193 veins were treated with n-butyl-2-cyanoacrylate in 122 patients, and all CACs performed during the study period were included. 76.7% (148/193) of the veins treated were great saphenous veins, 18.7% were small saphenous veins, and the remainder were accessory saphenous veins. The patients had an average BMI of 30.1, with an average age of 60.1 years. 62.3% of the patients were female.
Twenty-five of the patients (21.2%) experienced HSRs. Symptom onset ranged from 1 to 25 days, with a mean of 7.6 days. Nineteen patients (76%) had mild HSRs that resolved with no intervention or with NSAIDs, and six patients (24%) experienced moderate HSRs that resolved with steroids. Univariate analysis identified multiple risk factors for an HSR: younger age (55.38 years vs. 61.48 years without HSR, p = 0.0372), female sex (p = 0.0025), great saphenous vein intervention (p = 0.0388), lower CEAP score (2.71 vs. 3.42, p = 0.0055), history of provoked superficial vein thrombosis (28% vs. 8.6%, p = 0.0168), history of drug allergies (80% vs. 52.7%, p = 0.0210), and a longer treated vein segment (38.5 cm vs. 30 cm, p = 0.0205). There was no correlation identified between HSRs and the presence of skin conditions, prior cyanoacrylate treatment, history of inflammatory bowel disease, concomitant procedures, BMI, the minimum depth of the vein treated, or the diameter of the vein treated.
The overall vein closure rate post-CAC was 99.5%, and there was no significant difference in closure rates between patients with and without HSRs.